PEPCID RPD Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Pepcid Rpd, and when can generic versions of Pepcid Rpd launch?

Pepcid Rpd is a drug marketed by Merck and is included in one NDA.

The generic ingredient in PEPCID RPD is famotidine. There are eighteen drug master file entries for this compound. One hundred and thirty-eight suppliers are listed for this compound. Additional details are available on the famotidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pepcid Rpd

A generic version of PEPCID RPD was approved as famotidine by FRESENIUS KABI USA on April 16^th, 2001.

Sign Up

Summary for PEPCID RPD

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	83
Clinical Trials:	35
Formulation / Manufacturing:	see details
DailyMed Link:	PEPCID RPD at DailyMed

Drug patent expirations by year for PEPCID RPD

Recent Clinical Trials for PEPCID RPD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ohio State University Comprehensive Cancer Center	Phase 2/Phase 3
Leidos Life Sciences	Phase 2
United States Department of Defense	Phase 2

See all PEPCID RPD clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for PEPCID RPD

A02BA	H2-receptor antagonists
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for PEPCID RPD

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-001	May 28, 1998		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-002	May 28, 1998		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for PEPCID RPD

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-001	May 28, 1998	⤷ Sign Up	⤷ Sign Up
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-001	May 28, 1998	⤷ Sign Up	⤷ Sign Up
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-002	May 28, 1998	⤷ Sign Up	⤷ Sign Up
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-002	May 28, 1998	⤷ Sign Up	⤷ Sign Up
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-001	May 28, 1998	⤷ Sign Up	⤷ Sign Up
Merck	PEPCID RPD	famotidine	TABLET, ORALLY DISINTEGRATING;ORAL	020752-002	May 28, 1998	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for PEPCID RPD

See the table below for patents covering PEPCID RPD around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Italy	1165509	COMPOSTI GUANIDINO TIAZOLICI PARTICOLARMENTE UTILI COME INIBITORI DI SECREZIONE DI ACIDI GASTRICI E PROCEDIMENTO PER LA LORO PREPARAZIONE	⤷ Sign Up
Japan	S6056143		⤷ Sign Up
Germany	2951675		⤷ Sign Up
Spain	8100281		⤷ Sign Up
Denmark	93580		⤷ Sign Up
Australia	5597580		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Summary for PEPCID RPD

Recent Clinical Trials for PEPCID RPD

Anatomical Therapeutic Chemical (ATC) Classes for PEPCID RPD

Make Better Decisions: Try a trial or see plans & pricing